Results 101 to 110 of about 189,117 (342)

The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Polypharmacy is increasingly recognized as a relevant issue in diabetes care, but its prevalence and clinical relevance in individuals with type 1 diabetes remain underexplored. This study aimed to determine the prevalence of polypharmacy and to identify associated clinical and psychological factors. Participants were recruited from a tertiary diabetes
Namam Ali   +4 more
wiley   +1 more source

Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats [PDF]

open access: yes, 2015
Hypertension-induced structural remodeling of the left atrium (LA) has been suggested to involve the renin–angiotensin system. This study investigated whether treatment with an angiotensin receptor blocker, candesartan, regresses atrial remodeling in ...
Choisy, Stéphanie C.   +5 more
core   +1 more source

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Hypertension is a known modifiable risk factor for Alzheimer’s disease and related dementia (ADRD). However, it is unknown how variance in hypertension control, antihypertensive medications, and social determinants of health, such as social deprivation index (SDI), influence the risk of developing ADRD.
Eissa A. Jafari   +6 more
wiley   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

open access: yes, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
]   +15 more
core   +5 more sources

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park   +22 more
wiley   +1 more source

Comparative Mortality in Heart Failure on Guideline‐Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Guideline‐directed medical therapy (GDMT), including angiotensin receptor‐neprilysin inhibitor, angiotensin‐converting enzyme inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium‐glucose cotransporter‐2 inhibitors, has
Luca Monzo   +6 more
doaj   +1 more source

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]

open access: yes, 2018
Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian   +14 more
core   +4 more sources

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Home - About - Disclaimer - Privacy